Spyglass Pharma, Inc. (NASDAQ:SGP) Receives Consensus Recommendation of "Moderate Buy" from Analysts

Key Points

• Moderate Buy consensus from five analysts (four buys, one hold) with an average 1‑year target price of $47.00 per share.
• Major insider purchase: Director Ra Capital Management bought 3,690,000 shares at $16.00 each (~$59.04M), increasing its stake to 5,966,439 shares (a 162.1% rise) valued at roughly $95.5M.
• Market context: SGP was trading near $26.42 and sits below analyst targets, with a 12‑month range of $20.16–$32.44, implying potential upside from current levels.

Spyglass Pharma, Inc. (NASDAQ:SGP - Get Free Report) has earned a consensus rating of "Moderate Buy" from the five brokerages that are currently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $47.00.

Several research firms have commented on SGP. Leerink Partners downgraded shares of Spyglass Pharma to a "market perform" rating in a research report on Tuesday. Zacks Research raised Spyglass Pharma to a "hold" rating in a research report on Wednesday. Citigroup initiated coverage on Spyglass Pharma in a report on Tuesday. They set a "buy" rating and a $42.00 price objective on the stock. Wall Street Zen raised Spyglass Pharma to a "hold" rating in a research note on Tuesday, February 17th. Finally, Stifel Nicolaus started coverage on Spyglass Pharma in a report on Tuesday. They issued a "buy" rating and a $42.00 target price for the company.

Insider Buying and Selling at Spyglass Pharma

In other news, Director Ra Capital Management, L.P. acquired 3,690,000 shares of Spyglass Pharma stock in a transaction dated Monday, February 9th. The stock was acquired at an average cost of $16.00 per share, for a total transaction of $59,040,000.00. Following the completion of the purchase, the director owned 5,966,439 shares of the company's stock, valued at $95,463,024. This represents a 162.10% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this link.

Spyglass Pharma Trading Down 1.0%

Shares of SGP opened at $26.42 on Friday. Spyglass Pharma has a 12 month low of $20.16 and a 12 month high of $32.44.

About Spyglass Pharma

We are a late-stage biopharmaceutical company dedicated to transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. Our mission is to significantly improve the lives of patients with chronic eye conditions by developing durable drug delivery solutions that can empower patients and surgeons with confidence in long-term disease control and vision preservation. Our lead product candidate, the Bimatoprost Drug Pad-IOL System (BIM-IOL System), comprising novel, proprietary drug pads attached to our intraocular lens (IOL), is designed to be implanted during routine cataract surgery to reduce elevated intraocular pressure (IOP) in patients who have either open-angle glaucoma (OAG) or ocular hypertension (OHT).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.